Completed OBSERVATIONAL NCT04435028

Ketotifen: as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy

Ketotifen: Novel Use as a Cardioprotective Agent in Breast Cancer Patients Receiving Anthracycline-containing Chemotherapy as Well as the Potential Beneficial Effects of Ketotifen in the Hypothetical Management of COVID-19

Sponsor: Horus University

Conditions Breast Cancer Iron Chelation

Interventions Ketotifen 1 MG

Updated 4 times since 2020 Last updated: Jun 15, 2020 Started: Jan 14, 2019 Primary completion: Aug 13, 2019 Completion: Aug 13, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04435028, this observational or N/A phase trial focuses on Breast Cancer and Iron Chelation and remains completed. Sponsored by Horus University, it has been updated 4 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jul 2020 — Jan 2021 [monthly]

Completed

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Horus University

Data source: Horus University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Damietta, Egypt